Regeneron's Skin Cancer Treatment Fails Late-Stage Trial Goal

Drugmaker Regeneron saw its stock drop after its fianlimab-cemiplimab combination treatment for skin cancer did not achieve statistical significance in improving progression-free survival during late-stage trials.